Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Sevelamer Carbonate on Diabetic Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Evidence of CKD Stages II, III or IV~* Stage II CKD; eGFR 60-89 ml/min~* Stage III CKD: eGFR 30-59 ml/min~* Stage IV CKD: eGFR 15-29 ml/min~* Proteinuria (\>200 mg/day or 300 mg/gm creatinine on a spot urine) on urinalysis on two occasions within 18 months of recruitment~* Diagnosis of diabetes and receiving at least one medication for diabetes mellitus~* HbA1c\>6.5%~Exclusion criteria:~* Age \<18~* Patients receiving active treatment for hyperphosphatemia~* Biopsy proven renal disease other than diabetic nephropathy~* Hypophosphatemia~* Hypercalcemia~* Any history of significant gastrointestinal disorders~* Any history of significant gastrointestinal surgery such as ileostomy, colostomy and colectomy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sevelamer Carbonate (Type: EXPERIMENTAL): 1600 mg (two 800 mg in the form of tablets or powder to be diluted in water) TID with meals for 26 weeks
- calcium carbonate (Type: ACTIVE_COMPARATOR): 1200 mg of calcium carbonate TID with meals for 26 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).